Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients

Manuel, Oriol; Humar, Atul; Berutto, C.; Ely, Leticia; Giulieri, Stefano; Lien, Dale; Meylan, Pascal; Weinkauf, J.; Pascual, Manuel; Nádor, Roland G.; Aubert, John‐David; Kumar, Deepali

doi:10.1016/j.healun.2011.01.705

Cited by 46 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in healthy volunteers found that lower doses of antigen given intradermally produced similar antibody responses to those by the standard intramuscular influenza vaccine [75]. A randomized controlled trial in lung transplant recipients using 6 mg of antigen intradermally vs. 15 mg intramuscularly showed no significant differences in immunogenicity of influenza vaccine between strategies [55]. In kidney transplant recipients, response to the vaccine was better using the intradermal than the intramuscular route in a selected population of nonresponders to a previous vaccination [76].…”

Section: Novel Strategies For Improving Immunogenicity Of Influenza Vmentioning

confidence: 98%

See 1 more Smart Citation

Influenza vaccination in solid-organ transplant recipients

Cordero

Manuel²

2012

Current Opinion in Organ Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Novel Strategies For Improving Immunogenicity Of Influenza Vmentioning

confidence: 98%

“…The most common adverse event is pain at the injection site, which is usually of mild intensity and short lived [8 & , 55,56]. The potential relationship between vaccination and rejection has been a concern among transplant clinicians.…”

Section: Safety Of Influenza Vaccinementioning

confidence: 99%

Influenza vaccination in solid-organ transplant recipients

Cordero

Manuel²

2012

Current Opinion in Organ Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…[73][74][75][76] Immunogenicity has been explored also in immunocompromised patients: in transplanted patients, [77][78] in HIV-infected patients, 79 and in cancer patients. 80 Immunogenicity profiles of ID vaccines are not inferior to IM vaccines, as proven by some recently 89 Tsang and collaborators performed a randomized, controlled, multicenter, phase II study in older adults (≥65 years of age) who were randomly assigned to ID vaccine with 15μg (HA)/strain (n=636), ID vaccine with 21μg HA/strain (n=634), standard IM vaccine with 15μg HA/strain (n=319) and high-dose IM vaccine with 60μg HA/strain (n=320), respectively.…”

Section: Cutaneous Drug and Vaccine Deliverymentioning

confidence: 99%

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Bragazzi

Orsi

Ansaldi

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Influenza is a highly contagious respiratory acute viral disease which imposes a very heavy burden both in terms of epidemiology and costs, in the developed countries as well as in the developing ones. It represents a serious public health concern and vaccination constitutes an important tool to reduce or at least mitigate its burden. Despite the existence of a broad armamentarium against influenza and despite all the efforts and recommendations of international organisms to broaden immunization, influenza vaccination coverage is still far from being optimal. This, taken together with logistic and technical difficulties that can result into vaccine shortage, makes intra-dermal (ID) vaccines, such as Fluzone® ID and Intanza®, particularly attractive. ID vaccines are comparable and, in some cases, superior to intra-muscular/sub-cutaneous vaccines in terms of immunogenicity, safety, reactogenicity, tolerability and cross-protection profiles, as well as in terms of patient preference, acceptance and vaccine selection. Further advances, such as Fluzone® ID with alternative B strains and Quadrivalent Fluzone® ID or the possibility of self-administering the vaccines, make influenza ID vaccines even more valuable.

show abstract

“…28,29 Receipt of a lung transplant and the use of mycophenolate mofetil for immunosuppression are significant factors that contribute to decreased immunogenicity. 28,30 Multiple strategies have been attempted to improve the immunogenicity of IIV in SOT patients. These include intradermal administration or increasing the number of doses.…”

Section: Influenzamentioning

confidence: 99%

Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review

L'Huillier

Kumar

2015

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

The Solid Organ Transplantation (SOT) and Haematopoietic Stem Cell Transplantation (HSCT) population is continuously increasing as a result of broader indications for transplant and improved survival. Infectious diseases, including vaccine-preventable diseases, are a significant threat for this population, primarily after but also prior to transplantation. As a consequence, clinicians must ensure that patients are optimally immunized before transplantation, to provide the best protection during the early post-transplantation period, when immunosuppression is the strongest and vaccine responses are poor. After 3-6 months, inactivated vaccines immunization can be resumed. By contrast, live-attenuated vaccines are lifelong contraindicated in SOT patients, but can be considered in HSCT patients at least 2 years after transplantation, if there is no immunosuppression or graft-versus-host-disease. However, because of the advantages of live-attenuated over inactivated vaccines--and also sometimes the absence of an inactivated alternative--an increasing number of prospective studies on live vaccine immunization after transplantation are performed and give new insights about safety and immunogenicity in this population.

show abstract

Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients

Cited by 46 publications

References 24 publications

Influenza vaccination in solid-organ transplant recipients

Influenza vaccination in solid-organ transplant recipients

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review

Contact Info

Product

Resources

About